The Phase 2b INSIGHT study demonstrates that twice-daily bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) is highly effective and safe for treating HIV in patients receiving rifampicin-based tuberculosis therapy, achieving over 94 percent viral suppression at 24 weeks.